Skip to main content

Struthers Richard Scott's Form 4 filing

Crinetics Pharmaceuticals, Inc. (CRNX) · filed Apr 15, 2022

Accession no.
0001209191-22-024531
Filed
Apr 15, 2022
Trade date
Apr 13, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions. Open-market sales total $3.72M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Struthers Richard ScottCIK 0001746298Director, Officer (President & CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 13, 2022Common StockSSaleDisposed−24,674$25.42F2−$627,213.08844,774Indirect
Apr 13, 2022Common StockSSaleDisposed−44,793$26.52F3−$1,187,910.36799,981Indirect
Apr 13, 2022Common StockSSaleDisposed−69,176$27.53F4−$1,904,415.28730,805Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $25.4247 per share. The range of actual sales prices on the transaction date was $25.00 to $25.98 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request.

Referenced by the price of 1 transaction in Table I.

F3

The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $26.5229 per share. The range of actual sales prices on the transaction date was $26.02 to $27.005 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request.

Referenced by the price of 1 transaction in Table I.

F4

The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $27.5277 per share. The range of actual sales prices on the transaction date was $27.02 to $27.845 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)